These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32881584)

  • 1. The efficacy and safety of SGLT2 inhibitors combined with ACEI/ARBs in the treatment of type 2 diabetes mellitus: A meta-analysis of randomized controlled studies.
    Cai Y; Shi W; Xu G
    Expert Opin Drug Saf; 2020 Nov; 19(11):1497-1504. PubMed ID: 32881584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of combination therapy with sodium-glucose cotransporter 2 inhibitors and renin-angiotensin system blockers in patients with type 2 diabetes: a systematic review and meta-analysis.
    Tian B; Deng Y; Cai Y; Han M; Xu G
    Nephrol Dial Transplant; 2022 Mar; 37(4):720-729. PubMed ID: 33605424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of sodium glucose cotransporter 2 inhibitors plus standard care in diabetic kidney disease: A systematic review and meta-analysis.
    Woodhams LM; Chalmers L; Sim TF; Yeap BB; Schlaich MP; Schultz C; Hillis GS
    J Diabetes Complications; 2023 Jun; 37(6):108456. PubMed ID: 37127001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years.
    Liu XY; Zhang N; Chen R; Zhao JG; Yu P
    J Diabetes Complications; 2015; 29(8):1295-303. PubMed ID: 26365905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials.
    Bangalore S; Kumar S; Kjeldsen SE; Makani H; Grossman E; Wetterslev J; Gupta AK; Sever PS; Gluud C; Messerli FH
    Lancet Oncol; 2011 Jan; 12(1):65-82. PubMed ID: 21123111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis.
    Guo M; Gu J; Teng F; Chen J; Ma X; Chen Q; Pu Y; Jiang Z; Long Y; Xu Y
    Endocrine; 2020 Feb; 67(2):294-304. PubMed ID: 31900793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes.
    Vart P; Vaduganathan M; Jongs N; Remuzzi G; Wheeler DC; Hou FF; McCausland F; Chertow GM; Heerspink HJL
    Clin J Am Soc Nephrol; 2022 Dec; 17(12):1754-1762. PubMed ID: 36414316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
    Yang S; Zhao L; Mi Y; He W
    Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers in diabetic nephropathy: a systematic review and meta-analysis.
    Du YH; Guan CJ; Li LY; Gan P
    Ann Palliat Med; 2022 Mar; 11(3):1093-1101. PubMed ID: 35365039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Feng M; Lv H; Xu X; Wang J; Lyu W; Fu S
    Medicine (Baltimore); 2019 Jul; 98(30):e16575. PubMed ID: 31348290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Dholariya S; Dutta S; Singh R; Parchwani D; Sonagra A; Kaliya M
    Expert Opin Pharmacother; 2023; 24(18):2187-2198. PubMed ID: 37817422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Tang H; Cui W; Li D; Wang T; Zhang J; Zhai S; Song Y
    Diabetes Obes Metab; 2017 Jan; 19(1):142-147. PubMed ID: 27598833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis.
    Turgeon RD; Kolber MR; Loewen P; Ellis U; McCormack JP
    PLoS One; 2019; 14(2):e0212907. PubMed ID: 30817783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus with inadequate glycemic control on metformin: a meta-analysis.
    Jingfan Z; Ling L; Cong L; Ping L; Yu C
    Arch Endocrinol Metab; 2019; 63(5):478-486. PubMed ID: 31271575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials.
    Li WJ; Chen XQ; Xu LL; Li YQ; Luo BH
    Cardiovasc Diabetol; 2020 Aug; 19(1):130. PubMed ID: 32847602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
    Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension.
    Li EC; Heran BS; Wright JM
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD009096. PubMed ID: 25148386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
    Gebrie D; Getnet D; Manyazewal T
    Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in hypertensive patients with type 2 diabetes mellitus: A PRISMA-compliant systematic review and meta-analysis.
    Lv X; Zhang Y; Niu Y; Song Q; Zhao Q
    Medicine (Baltimore); 2018 Apr; 97(15):e0256. PubMed ID: 29642146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
    Min SH; Yoon JH; Hahn S; Cho YM
    Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.